We Think RenovoRx (NASDAQ:RNXT) Needs To Drive Business Growth Carefully [Yahoo! Finance]
RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer
RenovoRx, Inc. (NASDAQ: RNXT) had its price target raised by analysts at Ascendiant Capital Markets from $8.00 to $8.25. They now have a "buy" rating on the stock.
MyTomorrows partners with pancreatic cancer pressure group to drive trials [Yahoo! Finance]